Active Ingredient History

  • Now
Onapristone (INN) is a synthetic and steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering and described in 1984 but was never marketed. It is a silent antagonist of the progesterone receptor (PR), in contrast to the related antiprogestogen mifepristone. Moreover, compared to mifepristone, onapristone has reduced antiglucocorticoid activity, shows little antiandrogenic activity, and has 10- to 30-fold greater potency as an antiprogestogen. The medication was under development for clinical use, for instance in the treatment of breast cancer and as an endometrial contraceptive, but was discontinued during phase III clinical trials in 1995 due to findings that liver function abnormalities developed in a majority patients.   Wikipedia

  • SMILES: CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24
  • Mol. Mass: 449.64
  • ALogP: 5.16
  • ChEMBL Molecule:
More Chemistry
11 beta-(4-dimethylaminophenyl)-17 alpha-hydroxy-17 beta-(3-hydroxypropyl)-13 alpha-methyl-4,9-gonadien-3-one | estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11beta,13alpha,17alpha)- | onapristone | zk 299 | zk-299 | zk 98299 | zk 98.299 | zk-98299


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue